Ionis Pharmaceuticals Inc (IONS)

01:00 AM

Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.

01:00 AM

07:38 AM

Ionis to host 2025 virtual Annual Meeting of Stockholders | IONS Stock News - GuruFocus

07:38 AM

07:05 AM

Ionis to host 2025 virtual Annual Meeting of Stockholders - Business Wire

07:05 AM

May 05, 2025

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com

May 05, 2025

May 05, 2025

Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com

May 05, 2025

May 05, 2025

Oligonucleotide Delivery System Market Key Players Analysis - openPR.com

May 05, 2025

May 05, 2025

Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance

May 05, 2025

May 05, 2025

Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN

May 05, 2025

May 03, 2025

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View - MSN

May 03, 2025

May 02, 2025

Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow

May 02, 2025

May 02, 2025

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 02, 2025

May 02, 2025

Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates - simplywall.st

May 02, 2025

May 02, 2025

Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts - Investing.com Australia

May 02, 2025

May 02, 2025

Ionis Pharmaceuticals (IONS) Projects Revenue Growth with TRYNGO - GuruFocus

May 02, 2025

May 02, 2025

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 02, 2025

May 01, 2025

IONIS: Guggenheim Maintains Buy Rating but Lowers Price Target | - GuruFocus

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals (IONS) Receives Price Target Boost from HC Wainwright | IONS Stock News - GuruFocus

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim - GuruFocus

May 01, 2025

May 01, 2025

Polycythemia vera Market: Epidemiology, Therapies, - openPR.com

May 01, 2025

May 01, 2025

Ionis Earnings: Strong Commercial Launch of Tryngolza; Positive Long-Term Outlook - Morningstar

May 01, 2025

May 01, 2025

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts - Benzinga

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals (IONS) Target Price Increased to $50 After Strong Q1 | IONS Stock News - GuruFocus

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals Ups Revenue Forecast After Q1 Success - Finimize

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says - marketscreener.com

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim | IONS Stock News - GuruFocus

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlight - GuruFocus

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

May 01, 2025

May 01, 2025

Ionis Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks

May 01, 2025

Apr 30, 2025

Ionis Pharmaceuticals: Q1 Earnings Snapshot - MySA

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals (IONS) Boosts 2025 Revenue Guidance and St - GuruFocus

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge - Benzinga

Apr 30, 2025

Apr 30, 2025

Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com India

Apr 30, 2025

Apr 30, 2025

Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals (IONS) Q1 2025 Earnings: Revenue Surpasses - GuruFocus

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance

Apr 30, 2025

Apr 30, 2025

Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised - marketscreener.com

Apr 30, 2025

Apr 30, 2025

Ionis (IONS) Sees Strong Q1 Revenue with New Launches Fueling Gr - GuruFocus

Apr 30, 2025

Apr 30, 2025

Ionis reports first quarter 2025 financial results - BioSpace

Apr 30, 2025

Apr 30, 2025

IONIS PHARMACEUTICALS Earnings Results: $IONS Reports Quarterly Earnings - Nasdaq

Apr 30, 2025

Apr 30, 2025

Ionis reports first quarter 2025 financial results | IONS Stock News - GuruFocus

Apr 30, 2025

Apr 30, 2025

Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 EPS Loss $0.93, vs. FactSet Est of $1.10 Loss - marketscreener.com

Apr 30, 2025

Apr 29, 2025

Polycythemia Clinical Trials, Drugs, Key Companies, - openPR.com

Apr 29, 2025

Apr 29, 2025

New Harris Poll findings reveal HAE patients are unsatisfied wit - GuruFocus

Apr 29, 2025